Want to see CH:GALD full AI Analyst Report?
Top Page
Galderma Group AG
(GALD)
Select Model
Select Model
Rating:66Neutral
Price Target:
CHF171.00
▼(-0.35% Downside)
Action:Reiterated
Date:08/06/26
The score is driven primarily by improving financial performance (profitability and cash flow rebound plus materially lower leverage) and a supportive uptrend in the technicals. These positives are tempered by a demanding valuation (high P/E and minimal dividend yield) and some uncertainty around the consistency of revenue growth and cash-flow durability given prior volatility.
Positive Factors
High-margin profitability recovery
Galderma has combined meaningful revenue expansion with consistently high gross margins and a substantial EBIT-margin improvement. The swing from losses to solid profits indicates stronger operating leverage and a more resilient earnings base, supporting reinvestment and competitive execution over the next several quarters.
Negative Factors
Uneven revenue momentum
The year-over-year revenue decline indicates that earnings improvement has not yet been matched by consistently rising demand. Uneven top-line performance could limit operating leverage and make the durability of growth harder to assess across Galderma’s aesthetics, skincare, and therapeutic businesses.
Read all positive and negative factors
Positive Factors
Negative Factors
High-margin profitability recovery
Galderma has combined meaningful revenue expansion with consistently high gross margins and a substantial EBIT-margin improvement. The swing from losses to solid profits indicates stronger operating leverage and a more resilient earnings base, supporting reinvestment and competitive execution over the next several quarters.
Read all positive factors
Galderma Group AG (GALD) vs. iShares MSCI Switzerland ETF (EWL)
Market Cap
CHF37.00B
Dividend Yield0.22%
Average Volume (3M)369.75K
Price to Earnings (P/E)47.9
Beta (1Y)0.83
Revenue Growth15.78%
EPS Growth111.61%
CountryCH
Employees7,676
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)4.09
Shares Outstanding237,897,630
10 Day Avg. Volume438,816
30 Day Avg. Volume369,752
Financial Highlights & Ratios
PEG Ratio0.49
Price to Book (P/B)5.94
Price to Sales (P/S)9.24
P/FCF Ratio46.97
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF210.50Price Target Upside22.67% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)4.79
Revenue Forecast (FY)CHF6.38B
Galderma Group AG Business Overview & Revenue Model
Company Description
Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology....
How the Company Makes Money
Galderma makes money primarily by selling dermatology products across three main business areas: (1) Injectable Aesthetics: revenue from sales of aesthetic injectables used in-office by trained healthcare professionals (e.g., dermal fillers and ot...
Galderma Group AG Financial Statement Overview
Summary
Income Statement
76
Positive
Balance Sheet
73
Positive
Cash Flow
70
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.85B | 5.24B | 4.89B | 4.29B | 3.88B | 3.42B |
| Gross Profit | 3.92B | 3.61B | 3.40B | 2.99B | 2.65B | 2.38B |
| EBITDA | 1.33B | 1.22B | 1.06B | 806.91M | 640.35M | 520.60M |
| Net Income | 856.98M | 642.16M | 254.35M | -56.23M | -101.72M | -154.27M |
Balance Sheet | ||||||
| Total Assets | 13.56B | 13.39B | 12.62B | 12.26B | 12.42B | 12.53B |
| Cash, Cash Equivalents and Short-Term Investments | 841.26M | 780.00M | 457.00M | 361.53M | 234.18M | 286.17M |
| Total Debt | 2.70B | 2.75B | 2.76B | 4.83B | 5.66B | 5.67B |
| Total Liabilities | 5.33B | 5.24B | 4.83B | 6.98B | 7.95B | 7.99B |
| Stockholders Equity | 8.24B | 8.15B | 7.79B | 5.28B | 4.47B | 4.53B |
Cash Flow | ||||||
| Free Cash Flow | 1.03B | 1.03B | 213.00M | 43.35M | -49.77M | 67.69M |
| Operating Cash Flow | 1.16B | 1.19B | 488.00M | 162.58M | 114.93M | 195.66M |
| Investing Cash Flow | -138.57M | -154.00M | -287.10M | -182.43M | -76.21M | -533.40M |
| Financing Cash Flow | -640.14M | -728.00M | -51.08M | 148.82M | -74.45M | 317.14M |
Galderma Group AG Technical Analysis
Negative
171.60
Price Trends
173.00
Negative
168.81
Negative
161.18
Negative
Market Momentum
-3.36
Positive
27.16
Positive
9.86
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:GALD, the sentiment is Negative. The current price of 171.6 is above the 20-day moving average (MA) of 169.50, below the 50-day MA of 173.00, and above the 200-day MA of 161.18, indicating a bearish trend. The MACD of -3.36 indicates Positive momentum. The RSI at 27.16 is Positive, neither overbought nor oversold. The STOCH value of 9.86 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CH:GALD.
Galderma Group AG Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
82 Outperform | CHF284.80B | 23.24 | ― | 2.99% | -1.06% | 30.86% | |
78 Outperform | CHF237.20B | 24.28 | ― | 2.95% | -5.88% | -11.57% | |
66 Neutral | CHF37.00B | 47.90 | ― | 0.22% | 15.78% | 111.61% | |
66 Neutral | CHF4.13B | 25.99 | ― | 3.02% | 6.48% | -17.25% | |
62 Neutral | CHF30.08B | 55.90 | 7.04% | 1.17% | 0.81% | 165.32% | |
60 Neutral | CHF544.69M | -6.83 | ― | ― | ― | ― | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
* General Sector Average
CH:GALD
Galderma Group AG
158.35
14.66
10.21%
CH:DOCM
DocMorris
10.79
4.59
74.03%
CH:NOVN
Novartis AG
125.46
26.16
26.35%
CH:SDZ
Sandoz Group Ltd
68.24
20.80
43.84%
CH:GALE
Galenica AG
82.65
-2.71
-3.18%
CH:RO
Roche Holding Ltd
360.60
84.44
30.58%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.